Sera Prognostics

company

About

Sera Prognostics develops blood tests that are predictive of preterm birth, preeclampsia, and other pregnancy complications.

  • 51 - 100

Details

Last Funding Type
Series C
Last Funding Money Raised
$40M
Industries
Biotechnology,Health Care,Hospital,Medical,Medical Device
Founded date
Jan 1, 2008
Number Of Employee
51 - 100
Operating Status
Active

Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$108.43M
Sera Prognostics has raised a total of $108.43M in funding over 2 rounds. Their latest funding was raised on Jan 23, 2017 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 23, 2017 Series C $22.73M 1 LabCorp Detail
Jan 10, 2017 Series C $40M 1 LabCorp Detail
Jan 7, 2015 Series B $20M 1 Detail
Nov 18, 2014 Series B $5M 1 Detail
Nov 15, 2011 Series A $19.30M 1 Detail

Investors

Number of Lead Investors
Number of Investors
3
3
Sera Prognostics is funded by 3 investors. LabCorp and Upstart Life Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
LabCorp Yes Series C
Upstart Life Ventures Series B
Upstart Capital Series A